Results 151 to 160 of about 24,787 (310)
Incidence of Type 1 Inflammation-associated Diseases in Atopic Children Treated with Dupilumab [PDF]
Stanislaw J. Gabryszewski +5 more
openalex +1 more source
Happiness and Smell: Overlooked Factors in Endoscopic Sinus Surgery?
ABSTRACT Objective This study investigates the impact of functional endoscopic sinus surgery (FESS) on happiness levels in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and examines the factors influencing postoperative happiness. Methods This study included 55 patients (34 males, 21 females; mean age, 41.2 ± 14.7 years) who underwent
Tuğba Tulacı +4 more
wiley +1 more source
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab [PDF]
Erminia Ridolo +6 more
openalex +1 more source
Commentary: Response to “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study” [PDF]
Tien V. Nguyen +9 more
openalex +1 more source
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo +6 more
wiley +1 more source
The Clinical Efficacy and Safety of Dupilumab Monotherapy in Dystrophic Epidermolysis Bullosa: A Retrospective Real‐World Study [PDF]
Jian-Bo Wang +8 more
openalex +1 more source
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi +13 more
wiley +1 more source
Clinical &Experimental Allergy, Volume 55, Issue 3, Page 253-255, March 2025.
Robert Greig +4 more
wiley +1 more source

